Chronic Hepatitis News

Despite little contact with providers, patients in a minimal monitoring scenario achieved ‘cure’ of their hepatitis C virus, according to a presentation at The Digital Liver Meeting Experience.

Despite a global initiative to reduce hepatitis B mortality, few of the countries with the highest burden are on track to meet elimination targets, according to research presented at the Liver Meeting Digital Experience.

In a minimal monitoring – or “Minmon” – study, patients given a full regimen for hepatitis C virus and then remotely monitored achieved 95% sustained virologic response, according to a presenter at The Liver Meeting Digital Experience.

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma, according to a presenter at The Liver Meeting Digital Experience.

Despite guidelines to ensure proper screening, one study presented during the Liver Meeting Digital Experience showed only 42% of infants born to women with hepatitis C and cirrhosis are screened and followed for hepatitis C.

It is feasible for patients with negative HBV e-antigen chronic hepatitis B to discontinue nucleos(t)ide analogues therapy with low quantitative hepatitis B surface antigen levels, per a presentation at The Liver Meeting Digital Experience.

The Society for Healthcare Epidemiology of America updated its guidance for health care personnel with hepatitis B, hepatitis C or HIV in light of evidence of low transmission and advances in treatments.

Tenofovir alafenamide fumarate prevented mother to child transmission of hepatitis B without any safety concerns, according to study results.

Patients with hepatitis B treated with an investigational RNAi drug experienced reduced levels of surface antigens across different dose levels, according to research presented at The Digital International Liver Congress.

By 2040, researchers predict 75% of cirrhosis cases in North America will be due to nonalcoholic fatty liver disease with a nearly 350% increase in women born after 1980, according to a presenter at the Digital International Liver Conference.